natgillin/translations-raw huggingface dataset:
Use of a compound according to any one of claims 1 to 47 in the manufacture of a medicament for the treatment of type II diabetes. 
Uporaba pripravka u skladu s bilo kojim zahtjevom 1 do 31, 33, 35, 37, 40, 42, 45 i 47, naznačena time, da se koristi u izradi lijeka za liječenje dijabetesa tip II.
Variants within these ranges are also contemplated, particularly those having at least 80%, 85%, 90%, 95% or 99% identity to the corresponding portion of SEQ ID NO: 1 or 39. In certain embodiments, the GDF Trap polypeptide comprises, consists essentially of, or consists of, a polypeptide having an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to amino acid residues 25-131 of SEQ ID NO: 1 or 39. 
Polipeptid za uporabu prema zahtjevu 2, pri čemu polipeptid sadrži sekvencu aminokiseline koja je (a) barem 95 % identična sekvenci aminokiselina 29-109 SEQ ID NO: 1, (b) barem 95 % identična sekvenci aminokiselina 25-118 SEQ ID NO: 1, (c) barem 95 % identična sekvenci aminokiselina 25-128 SEQ ID NO: 1 ili (d) barem 97 % identična sekvenci aminokiselina 25-131 SEQ ID NO: 1.
two adjacent substituents selected from R3, R4, R5, R6 and R7 may together with the aromatic ring they are attached to form a 5-7 membered, saturated or unsaturated ring containing carbon and one or two heteroatoms selected from N, O or S, and optionally substituted with an (C1-C6) alkoxy group where the remaining three substituents selected from R3, R4, R5, R6 and R7, which do not take part of the ring, are independently selected as stated above; 
a ga HR P20120835 T1 oRa RsiReg su nezavisno nitro, ili o dva susjedna supstituenta izabrana između R3, R4, Rs, Rg 1 R; mogu zajedno s atomima ugljika za koji su spojeni formirati 5-7-eročlani, zasićeni ili nezasićeni prsten koji sadrži ugljik i po izboru jedan ili dva heteroatoma izabrana između N, O ili S, 1 po izboru je supstituiran skupinom (Ci-Cg) alkoksi.
The transdermal delivery device of claim 1, where the matrix comprises a material selected from the group consisting of polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethylacrylate copolymers, ethylenevinyl acetate copolymers, silicones, rubber, rubberlike synthetic homo-, co- or block polymers, polyacrylic esters and the copolymers thereof, polyurethanes, polyisobutylene, chlorinated polyethylene, polyvinylchloride, vinyl chloride-vinyl acetate copolymer, polymethacrylate polymer (hydrogel), polyvinylidene chloride, poly(ethylene terephthalate), ethylene-vinyl alcohol copolymer, ethylene vinyloxyethanol copolymer, silicones (e.g., silicone copolymers such as polysiloxane-polymethacrylate copolymers), cellulose polymers (e.g., ethyl cellulose, and cellulose esters), polycarbonates, polytetrafluoroethylene and mixtures thereof. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da je sloj koji sadrži lijek matrični sloj, i da matrica poželjno sadrži materijal odabran iz skupine koja se sastoji od polietilena, polipropilena, etilen/propilen kopolimera, etilen/etilakrilat kopolimera, etilenvinil acetatnih kopolimera, silikona, gume, sintetičkih homo-, ko- ili blok polimera sličnih gumi, poliakrilinih estera i njihovih kopolimera, poliuretana, poliizobutilena, kloriranih polietilena, polivinilklorida, vinil klorid-vinil acetat kopolimera, polimera polimetakrilata (hidrogel), poliviniliden klorida, poli(etilen tereftalata), etilen-vinil alkohol kopolimera, etilen-viniloksietanol kopolimera, silikona (npr. silikon kopolimera kao što su polisiloksan-polimetakrilat kopolimera), celuloznih polimera (npr. etil celuloze i estera celuloze), polikarbonata, politetrafluoroetilena i njihovih smjesa.
The cable may be manufactured from a material such as steel, wire rope, aramid fibers, liquid crystal polymer fibers, ultra-high-molecular-weight polyethylene fibers, and the like. 
Sustav (10) za generiranje snage prema Zahtjevu 7, gdje je najmanje jedan kabel izrađen od materijala izabranog iz grupe koja sadrži čelik, žičanu užad, vlakna aramida, vlakna tekućih kristalnih polimera, vlakna polietilena ultra visoke molekularne težine.
In solution fructose, for example, can exist mostly in a 6-membered pyranose form and/or its 5-membered furanose form. (See Figure 1). 
U otopini fruktoza, na primjer, može postojati većinom u 6-članom piranoznom obliku i/ili svojem 5-članom furanoznom obliku (v. sliku 1).
providing a compound of Formula IIIb: and treating the compound of Formula IIIb with an organometallic compound of Formula IV: 
[image] i tretiranja spoja Formule IIIb s organometalnim spojem Formule IV:
The ability of compounds of formula I to inhibit tumor growth in mice was tested as follows. 
Sposobnost spojeva formule I da inhibiraju rast tumora u miševa ispitana je kako slijedi.
In order to succeed in incorporating to the optimum extent (without the dimensions of the cabinet 2 becoming excessive) all the components inside a single cabinet 2, it was necessary to solve a series of technical problems. 
Da bi se postigla optimalna veličina (a da pri tome nisu dimenzije ormarića suviše velike) svih komponenti koje su unutar pojedinog ormarića, bilo je potrebno riješiti niz tehničkih problema.
The foil lined tube mouthend piece, of the same type as used in Example 1, enclosed the rear 2 mm of the fuel element and the substrate. 
Dio usnog kraja od cijevi koja je obložena [olijom, istog tipa kao što se koristi u Primjeru 1, okruživao je zadnjih 2 mm gorivog elementa i supstrata.
The pharmaceutical composition according to Claim 3, wherein the extra-granular excipients comprise one or more: 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što ekstragranularne pomoćne tvari sadrže jedno ili više od sljedećeg:
The purification process, starting from the captured material according to above (1), is described in detail below. 
Proces pročišćavanja, počinjući od materijala koji je bio ulovljen u koraku (1) opisan je detaljno u pasusu koji slijedi.
The method of claims 1 or 2 wherein in step (B) said cells are initially cultured cell under normal culture conditions and then said osmolality is increased to an amount sufficient to increase expression of said second protein of interest. 
Postupak u skladu s patentnim zahtjevima 1 ili 2, naznačen time, da su u koraku (B) spomenute stanice na početku stanice u kulturi pod normalnim uvjetima uzgoja i potom se spomenuta osmolalnost povećava do omjera koji je dovoljan za povećanje ekspresije spomenutog drugog protema od interesa.
is halogen, cyano, nitro, carboxyl, sulfonic group, C1-3alkyl, C1-3alkoxy, C1-3alkylamino or di(C1-3alkyl)amino, n is 2, wherein R1 can be identical or different, said C1-3alkyl, C1-3alkoxy, C1-3alkylamino and di(C1-3alkyl)amino can optionally be substituted by 1, 2 or 3 substituents independently selected from the group consisting of: fluoro, chloro, cyano, hydroxyl and carboxyl; 
R' je halogen, cijano, nitro, karboksil, sulfonska skupina, Cr3alkil, Ci3alkoksi, C,sgalkilamino ili di(Ci salkiljamino, n je 2, gdje R' može biti identičan ili različit, spomenuti Cigalkil, C,salkoksi, Cisalkilamino i di(C,3alkiljamino mogu izborno biti supstituirani s 1, 2 ili 3 supstituenta nezavisno odabranih iz skupine koja se sastoji od: fluora, klora, cijano, hidroksila i karboksila;
The isolated antibody or antigen binding fragment thereof that binds to CD38 according to claim 1, which comprises the three H-CDRs in SEQ ID NO: 21 and the three L-CDRs depicted in SEQ ID NO: 51. 
Humano specifično anti-CD38 antitijelo koje sadrži: (i) H-CDRI, H-CDR2 i H-CDR3 regiju prikazanu u sekvenci SEQ ID NO: 21, i L-CDRI, L-CDR2 i L-CDR3 regiju prikazanu u sekvenci SEQ ID NO: 51;
Use according to claims 20 or 30 wherein said enteroendocrine cell is of GLUTag-Fro cell line. 
Uporaba u skladu sa zahtjevom 20 ili 30, naznačena time, da navedena enteroendokrina stanica je GLUTag-Fro stanične linije.
The compound of Claim 1, or a pharmaceutically acceptable salt or an isomer thereof, wherein X is CH2; is N; and Y3 are respectively and independently CR5; 
Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje X je CH2; Y'jeN; Y7i Y? su respektivno i nezavisno CR";
The method of any one of claims 1 to 14, wherein the (±)-A9-tetrahydrocannabinol comprises at least 95%, preferably at least 98%, more preferably at least 99% by weight of trans-(-)-A9-tetrahydrocannabinol and trans-(+)-A9-tetrahydrocannabinol based on the total amount of cannabinoids. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time da (±)-A9-tertahidrokanabinol sadrži barem 95%, poželjno barem 98%, poželjnije barem 99% težinski trans-(-)-A9-tertahidrokanabinola i trans-(+)-A9-tertahidrokanabinola u odnosu na ukupnu količinu kanabinoida.
The second screw 24 has, at an end adjacent the second hole 11, an annular head 26 having a diameter greater than that of the second hole 11 so as to abut on the perimetral edge of such second hole 11 and having the possibility of freely rotating. 
Drugi vijak 24, na kraju susjednom do druge rupice 11, ima prstenastu glavu 26 koja ima promjer veći od promjera druge rupice 11, tako da na obodnom rubu dodiruje tu drugu rupicu 11 i ima mogućnost slobodne rotacije.
The powder is then heated in an oven with dry atmosphere for 2 h. with a ramp of 4 h. to the temperature of the crystal formation temperature (460° C. for this batch) of the amorphous zirconia powder. 
Prašak je zatim zagrijavan u peći sa suhom atmosferom kroz 2 sata s vremenom od 4 h za postizanje temperature tvorbe kristala (460 "C za ovaj uzorak) amorfnog praška cirkonijeva oksida.
Use of the compound of formula I or a salt, a N-oxide or a salt of a N-oxide of this compound as claimed in claim 7 for the production of pharmaceutical compositions for the treatment of psoriasis. 
Uporaba spoja formule I prema zahtjevu 5, naznačena time, da je za proizvodnju farmaceutskih sastava za liječenje bronhijalne astme, COPD-a, psorijaze ili atopičnog ekcema.
mM acetic acid containing 0.9% sodium chloride adjusted to pH 4.0 with sodium hydroxide. The compound of the invention is dispersed in the alcohol and dissolved in the propylene glycol by the aid of heat. 
2-hidroksipropil-B-ciklodekstrina u 50 mM do zasićenja octenoj kiselini s 0,9 % natrijevog klorida, podešeno natrijevim hidroksidom do pH 4,0 100 ml Spoj prema ovom izumu dispergira se u alkoholu, te otopi u propilen-glikolu uz grijanje.
After frying, the core temperature was 74 - 85°C. A small loss of weight was observed due to loss of water from the substrate but this is mostly compensated for by the uptake of oil. A method of manufacture of a microwave or thermally cookable or reheatable food product wherein the product comprises a substrate comprising pieces of poultry, fish, red meat, vegetable, fruit or dairy food; the method comprising the steps of: 
Postupak za proizvodnju prehrambenog proizvoda koji se može mikrovalno ili termalno kuhati ili ponovo zagrijavati, pri čemu proizvod sadrži supstrat koji sadrži komade peradi, ribe, crvenog mesa, povrća, voća ili mliječnog proizvoda; postupak sadrži korake: nanošenja omotača od kompozicije vodenog omotača na supstrat; pri čemu, kompozicija vodenog omotača sadrži vodu i 0.1 do 5% smjese koja sadrži po suhoj težini slijedeće sastojke: celulozna guma
The composition of claim 7, wherein said Crohn's disease is gastroduodenal Crohn's disease, jejunoileitis, ileitis, ileocolitis, or Crohn's colitis. 
Matične stanice posteljice za uporabu u skladu s patentnim zahtjevom 4, naznačenu time što je navedena Crohnova bolest gastroduodenalna Crohnova bolest, jejunoileitis, ileitis, ileokolitis, ili Crohnov kolitis.
Suitable carriers for powders and tablets are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. 
Prikladne podloge za praške i tablete su magnezij karbonat, magnezij stearat, talk, šećer, laktoza, pektin, dekstrin, škrob, želatina, tragakant, metilceluloza, natrij karboksimetilceluloza, voskovi niskog tališta, kakao maslac i slično.
The compound of any of claims 1 to 10, wherein the spacer of the compound of formula I comprises one covalent bond with a residue of a biotin analogue of the formula -(CH2)4-NR- BT, wherein R is H or (1-4C)alkyl and BT is the residue 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što razmaknica u spoju formule I sadrži jednu kovalentnu vezu s ostatkom biotinskog analoga formule -Â«(CH2)u-NR-BT, gdje R je H ili (1-4C)alkil, a BT je ostatak H
In another embodiment of the beverage dispensing assembly the base unit comprises a resilient cup-shaped part, said cup-shaped part comprising a side wall, a bottom adapted for cooperating with a central elevation on the base part, and a hollow piercer the base unit further comprising a closure formed on an upper rim of the cup-shaped part. 
U drugoj izvedbi sklopa za točenje pića osnovna jedinica obuhvaća elastičan dio u obliku čašice, pri čemu dio oblika čašice obuhvaća bočnu stijenku, te dno prilagođeno tako da djeluje zajedno sa središnjim povišenjem na osnovnom dijelu, a šuplje bušilo osnovne jedinice uključuje, nadalje, zapor izrađen na gornjem rubu dijela oblika šačice.
The method of claim 1, wherein, when the upper intra prediction mode or the left intra prediction mode is unavailable, the upper intra prediction mode or the left intra prediction mode is set to a DC mode. 
Uređaj prema zahtjevu 1, naznačen time da je način unutarokvirnog predviđanja kodiran korištenjem gornjeg načina unutarokvirnog predviđanja 1 lijevim načinom unutarokvirnog predviđanja, i kada je gornji način unutarokvirnog predviđanja ili lijevi način unutarokvirnog predviđanja nedostupan, gornji način unutarokvirnog predviđanja ili lijevi način unutarokvirnog predviđanja je namješten na DC način.
A genic expression adenoviral hybrid vector according to claim 1, characterized in that element iv forms a replicon functionally controlled by the promoter iii, and in that the alphaviral subgenomic promoter in iv.c) functionally controls the expression of the exogenous gene of interest. 
Adenovirusni hibridni vektor sa genskom ekspresijom prema bilo kojem od patentnih zahtjeva 9 do 17, naznačen time što element iv. obrazuje funkcionalni replikon koji kontrolira promotor ili, i gdje alfavirusni subgenomski promoter sadržan u iv.c) funkcionalno kontrolira ekspresiju egzogenog gena od interesa,
comprises a heavy chain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:88; 
jaki lanac koji ima identitet sekvence barem 90% od aminokiselinske sekvence od SEQ ID NO:88, i/ili
removing the amino-protecting group, P, from the compound of formula 3 or a salt thereof, to provide a compound of formula I or a salt thereof. 
g A Å e ili njegova sol, gdje je L izlazna skupina a P je amino-zaštitna skupina; 1 (b) uklanjanje amino-zaštitne skupine, P, iz spoja formule 3 ili njegove soli, da se dobije spoj formule I ili njegova sol.
The deinterleaved bits are error-correction-decoded. 
"Deinsertirani bitovi su kodirano ispravljanje pogreške |
More particularly, the compounds of the invention are active at the TRPVI receptor as demonstrated by their ability to inhibit capsaicin and low pH activation of the TRPVI ion channel as follows: 
Pobliže, spojevi formula (1) i (Ia) djeluju na TRPVI receptor, kako je to pokazano s njihovom sposobnošću da inhibiraju kapsaicin i aktivaciju TRPVI ionskog kanala pri niskoj pH vrijednosti kako slijedi:
A recent study has assessed the outcome of drug dependent mothers and influence of buprenorphine maintenance on neonatal morbidity (Jernite et al., Arch. 
Novije ispitivanje je procijenilo posljedice održavanja buprenorfinom kod ovisnih majka i utjecaj na neonatalni morbiditet (Jernite et al., Arch.
During the 30-second interval, display 112 will flash “clean”. 
Tijekom intervala od 30 sekundi displej 112 će povremeno bljeskanjem davati obavijest "čišćenje" ("clean").
A clip (7') as claimed in claim 19, wherein the heel portion (72') comprises a bend greater than 90°. 
Držač (7') u skladu s patentnim zahtjevom 19, kod kojega predio s petom (72') ima savijeni dio koji je savijen pod kutom koji je veći od 90".
A packaging according to claim 9 or 10, wherein the metal part/layer covering the back part comprises slips that may be bent around an upper and lower edge of the back part in order to attach the metal part/layer. 
Pakiranje u skladu s patentnim zahtjevom 9 ili 10, naznačeno time, što metalni dio/sloj koji prekriva stražnji dio sadržava trake koje mogu biti savijene oko gornjeg i donjeg ruba stražnjeg dijela, da bi se na taj način pričvrstio metalni dio/sloj.
The process according to any one of embodiments 12-22, wherein the enzyme is SEQ IS NO: 134. The process of embodiment 22, wherein the compound of formula (IIA) is converted to a salt of formula (IIB): prior to reaction with the compound of formula (IIIA). 
CI h i pri čemu je enzim SEQ ID NO: 134. njegove soli ili Postupak prema patentnom zahtjevu 8, naznačen time, što se spoj formule (ILA) pretvara u sol formule (IIB):
reacting the aminooxy group of the oligosaccharide with the at least one carbonyl group of the lysosomal enzyme, thereby coupling the oligosaccharide to the lysosomal enzyme, wherein the oligosaccharide comprising an aminooxy group is 
Postupak prema zahtjevu 11 naznačen time da protein je glikoprotein i barem jedna karbonilna skupina se dobiva oksidacijom glikoproteina s perjodatom.
U.S. Pat. No. 6,565,877 describes a taste-masked composition containing a bitter tasting drug, such as clarithromycin, and a combination of two enteric polymers comprising a methacrylic acid copolymer and a phthalate polymer, wherein the ratio of methacrylic acid copolymer to phthalate polymer is between 1:9 or 9:1. 
U.S. Patent No, 6,565,877 opisuje pripravak maskiranog okusa koji sadrži lijek gorkog okusa, poput klaritromicina i kombinaciju dvaju enteričkih polimera koji sadrže kopolimer metakrilne kiseline 1 ftalatni polimer, pri čemu je odnos kopolimera metakrilne kiseline prema ftalatnom polimeru između 1: 919:1.
The compound or pharmaceutically acceptable salt thereof for use according to claim 13 wherein the neuropathic pain is fibromyalgia or peripheral neuropathy. 
Spoj ili farmaceutski prihvatljiva sol tog spoja za primjenu u skladu sa patentnim zahtjevom 13 pri čemu neuropatska bol je fibromijalgija ili periferna neuropatija.
The formulation according to claim 8, wherein the disease is asthma or chronic obstructive pulmonary disease. 
Formulacija prema patentnom zahtjevu 8, naznačena time da bolest jest astma ili kronična opstruktivna bolest pluća.
reacting said 5'-hydroxyl group with a second protecting group consisting of acyl, base-labile trialkyl silyl ether, or fluoride labile silyl ether; and reacting said nucleoside base with a third protecting group which is an acyl group or a formamidinyl group; 
reakcija navedene 5’-hidroksil-skupine s drugom zaštitnom skupinom koja se sastoji od sljedećih: acil, bazično labilni trialkilsilileter, ili fluoridno labilni silileter; i reakcija navedene nukleozidne baze s trećom zaštitnom skupinom koja je acil-skupina ili formamidinil-skupina;
A method for inhibiting VR1 function in a cell, comprising in vitro contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable compound of claim 1. 
Postupak za inhibiranje VR1 funkcije u stanici, naznačen time, da se sastoji od in vitro dovođenja u dodir stanice, sposobne da eksprimira VRI, s učinkovitom količinom spoja iz patentnog zahtjeva 1 ili njegove farmacoutski prihvatljive soli.
A medicine according to claim 46 or 47, wherein the cancer is selected from breast cancer, colon cancer, prostate cancer, lung cancer, gastric cancer, ovarian cancer, endometrial cancer, renal cancer, hepatocellular carcinoma, thyroid cancer, uterine cancer, esophageal cancer, squamous cell carcinoma, leukemia, osteosarcoma, melanoma, glioblastoma, neuroblastoma and pancreatic cancer. 
Lijek, spoj ili njegova sol, ili kristal istog, ili farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 32, gdje je rak odabran od raka dojke, raka debelog crijeva, raka prostate, raka pluća, raka želuca, raka jajnika, raka endometrija, raka bubrega, hepatocelularnog karcinoma, raka tiroide, raka maternice, raka ezofagusa, karcinoma skvamoznih stanica, leukemije, osteosarkoma, melanoma, glioblastoma, neuroblastoma i raka gušterače.
The message controller as claimed in claim 1, wherein the message controller is adapted to send a fresh routing query to a HSS. 
Kontroler poruka prema bilo kojem od prethodnih Zahtjeva, pri čemu je kontroler poruka prilagođen da pošalje novi upit za dostavljanje informacija o rutiranju prema HSS-u.
The method according to claim 1, wherein for assembly between the upper and the membrane, thermo-adhesive glue is distributed on a surface of said membrane in contact with the upper so as to not compromise vapor permeability of the membrane. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se radi dobivanja spoja između gornjišta (12) i membrane (13) termoadhezivno ljepilo nanosi se na površinu navedene membrane (13) koja je u kontaktu s gornjištem (12) kako se ne bi ugrozila njezina paropropusnost.
The pharmaceutical composition of clause 16, wherein the drug particles have an average particle size of less than about 400 µm, the rapidly dispersing granules have an average particle size of less than about 300 µm, and the disintegrant and sugar alcohol and/or saccharide have an average particle size of less than about 30 µm. The pharmaceutical composition of clause 16, wherein the drug particles have an average particle size of less than about 4 µm, the rapidly dispersing granules have an average particle size of less than about 300 µm, and the disintegrant and sugar alcohol and/or saccharide have an average particle size of less than about 30 µm. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 10, naznačeno time da čestice lijeka imaju prosječne veličinu čestica manje od 400 um, dok brzo raspršujuće granule imaju prosječnu veličinu čestica manje od 300 um, i sredstvo za raspadanje i šećerni alkohol i/ili saharid imaju prosječnu veličinu čestica manju od 30 um; ili pri čemu je budezonid ili njegov solvat ili estar raspoređen po površini ekscipijensa, dok brzo raspršujuće granule imaju prosječnu veličinu čestica manju od 300 um, i sredstvo za raspršivanje i šećerni alkohol i/ili saharid imaju prosječnu veličinu čestica manju od 30 um.
A method according to claim 1 wherein the polymeric material in the composite layer is foamed and an outer layer of the foamed polymeric material is removed while uncoagulated whereby the outer surface of the polymeric layer has an open porous structure. 
Postupak sukladno patentnom zahtjevu 1, pri čemu je taj polimerni materijal kompozitni sloj pjenast i vanjski sloj pjenastog polimernog materijala se uklanja dok je nekoaguliran pri čemu vanjska površina polimernog sloja ima otvorenu poroznu strukturu.
-NRB5CORB6 wherein RB5 is a hydrogen atom or a C1-4 alkyl group, and RB6 is a hydrogen atom, a C1-4 alkyl group, a C3-12 carbon ring group or a heterocyclic group, 
-NRB5CORB6, gdje je RB5 atom vodika ili C1-4 alkilna skupina, a RB6 je atom vodika, C1-4 alkilna skupina, prstenasta skupina s C3-12 ugljika ili heterociklička skupina,
Process according to claim 4 characterized in that the compound obtained is enantiomerically pure (R)-pirlindole as (S)-mandelate salt. 
Proces u skladu sa patentnim zahtjevom 4 naznačen time da dobiveni spoj je enantiomerno čist (R)-pirlindol kao (S)-mandelat sol.
The method of claim 4 wherein the disease or disorder is cancer. The method of claim 5 wherein the cancer is selected from the group consisting of breast cancer, lung cancer, gastric cancer, ovarian cancer and hepatocellular cancer. 
Antitijelo za primjenu iz patentnog zahtjeva 14 konjugat za primjenu iz patentnog zahtjeva 14 ili farmaceutska kompozicija za primjenu iz patentnog zahtjeva 14 gdje bolest ili poremećaj je odabran iz grupe koja se sastoji od raka dojke, raka pluća, raka želuca, raka jajnika i hepatocelularnog raka.